JAB-23000 / Jacobio Pharma - LARVOL DELTA

Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors. (PubMed, Molecules) - "Various KRAS-directed inhibitors have been developed, including the FDA-approved drugs sotorasib and adagrasib, KRAS-G12D inhibitor MRTX1133, and KRAS-G12V inhibitor JAB-23000, etc. The different strategies greatly promote the development of KRAS inhibitors. Herein, the strategies are summarized, which would shed light on the drug discovery for both KRAS and other "undruggable" targets."

Journal • Review • Oncology • Targeted Protein Degradation • KRAS

Jacobio Announces Annual Results of 2021, R&D Investment Increases 83% (PRNewswire) - "...There are seven preclinical programs of Jacobio that are all new targets and are expected to submit IND applications as one of the first three globally. These include JAB-24114 (an undisclosed target in tumor metabolic pathway), JAB-BX300 (an undisclosed target in the RAS pathway), which is scheduled to submit an IND application in 2022, and JAB-26766...to submit an IND application during 2022 to 2023...JAB-23400 (KRASmulti inhibitor), JAB-22000 (KRAS G12D inhibitor), JAB-23000 (KRAS G12V inhibitor), JAB-30000 (P53 inhibitor) will submit IND applications during 2023 to 2024...Jacobio will submit a registrational clinical trial application for KRAS G12C inhibitor (JAB-21822) in China in 2022 and is expected to submit a New Drug Application (NDA) during 2023 to 2024..."

IND • New trial • Non-US regulatory • Oncology